Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Mulls Putting Cash Behind Interest In Buying L’Oreal’s Shares

This article was originally published in The Tan Sheet

Executive Summary

Sanofi has the cash to buy back about $12 billion of its shares currently owned by beauty firm L’Oreal, if those shares were up for sale, Sanofi CEO Viehbacher says. L’Oreal CEO Agon suggested in recent earnings call that the firm could seek cash for future deals through the sale of its 9% stake in Sanofi.

You may also be interested in...



Sanofi Names Regenauer Global OTC Head, Underscores Consumer Focus

Sanofi-Aventis further highlights its consumer health focus by naming Hans Regenauer to head its global OTC business as the firm works to close its acquisition of OTC and personal care firm Chattem

With $1.9 Bil. Bid For Chattem, Sanofi Knocks On Door To U.S. OTC Market

With its $1.9 billion bid for personal-care and over-the-counter drug manufacturer Chattem, French pharmaceutical giant Sanofi-Aventis stands to gain a toehold in the sizeable U.S. consumer health sector and beef up its presence in emerging markets

Sanofi Counts On OTC Switches Adding $1bn In Consumer Revenues By 2026

Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.

Topics

Related Companies

UsernamePublicRestriction

Register

PS106651

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel